Idorsia's insomnia drug works in late-stage clinical trial [Reuters]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Reuters
Idorsia's insomnia drug works in late-stage clinical trial ZURICH, April 20 (Reuters) - Swiss drugmaker Idorsia Ltd’s experimental insomnia drug daridorexant produced positive results in a late-stage clinical trial, the company said on Monday. The first pivotal phase-3 study investigating 25 and 50 mg doses of the dual orexin receptor antagonist in 930 adult and elderly patients showed it helped people fall asleep and stay asleep and improved their daytime performance, Idorsia said. It found no residual effect in the morning, and no evidence of rebound or withdrawal symptoms when treatment stopped, it added in a statement. “While we designed daridorexant to have the optimal profile for a sleep medicine, I am nonetheless stunned by the results,” Chief Executive Jean-Paul Clozel said. Clozel told Reuters in February he was sticking to plans to seek regulatory approval for daridorexant, also called DORA, this year and hoped for a worldwide launch at the close of 2021 or the start of 2022
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Catalyst Watch: Intel earnings, drama in Davos, and the fight for Warner Bros. [Seeking Alpha]Seeking Alpha
- Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz [Yahoo! Finance]Yahoo! Finance
- Big pharma and investors re-engage in CGTs and race to scale [Yahoo! Finance]Yahoo! Finance
- 2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income [Yahoo! Finance]Yahoo! Finance
- TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website